Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis

Detalhes bibliográficos
Autor(a) principal: Santos,Anna Raquel Ribeiro dos
Data de Publicação: 2019
Outros Autores: Serufo,Ângela Vieira, Figueiredo,Maria Marta, Godoi,Lara Carvalho, Vitório,Jéssica Gardone, Marcelino,Andreza Pain, Avelar,Daniel Moreira de, Rodrigues,Fernandes Tenório Gomes, Machado-Coelho,George Luiz Lins, Medeiros,Fernanda Alvarenga Cardoso, Jerônimo,Selma Maria Bezerra, Oliveira,Edward José de, Nascimento,Frederico Crepaldi, Teixeira,Santuza Maria Ribeiro, Gazzinelli,Ricardo Tostes, Nagem,Ronaldo Alves Pinto, Fernandes,Ana Paula
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Memórias do Instituto Oswaldo Cruz
Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100310
Resumo: BACKGROUND Visceral Leishmaniasis (VL) is an infectious disease that is a significant cause of death among infants aged under 1 year and the elderly in Brazil. Serodiagnosis is a mainstay of VL elimination programs; however, it has significant limitations due to low accuracy. OBJECTIVE This study aimed to evaluate three recombinant Leishmania infantum proteins (rFc, rC9, and rA2) selected from previous proteomics and genomics analyses to develop enzyme-linked immunosorbent assay (ELISA) and immunochromatographic tests (ICT) for the serodiagnosis of human VL (HVL) and canine VL (CVL). METHODS A total of 186 human (70 L. infantum-infected symptomatic, 20 other disease-infected, and 96 healthy) and 185 canine (82 L. infantum-infected symptomatic, 27 L. infantum-infected asymptomatic, and 76 healthy) sera samples were used for antibody detection. FINDINGS Of the three proteins, rA2 (91.5% sensitivity and 87% specificity) and rC9 (95.7% sensitivity and 87.5% specificity) displayed the best performance in ELISA-HVL and ELISA-CVL, respectively. ICT-rA2 also displayed the best performance for HVL diagnosis (92.3% sensitivity and 88.0% specificity) and had high concordance with immunofluorescence antibody tests (IFAT), ELISA-rK39, IT-LEISH®, and ELISAEXT. ICT-rFc, ICT-rC9, and ICT-rA2 had sensitivities of 88.6%, 86.5%, and 87.0%, respectively, with specificity values of 84.0%, 92.0%, and 100%, respectively for CVL diagnosis. MAIN CONCLUSIONS The three antigens selected by us are promising candidates for VL diagnosis regardless of the test format, although the antigen combinations and test parameters may warrant further optimisation.
id FIOCRUZ-4_9e50a969ab76de9af7eb220d7dbd2b6f
oai_identifier_str oai:scielo:S0074-02762019000100310
network_acronym_str FIOCRUZ-4
network_name_str Memórias do Instituto Oswaldo Cruz
spelling Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosisvisceral leishmaniasisrecombinant proteinsdiagnosisELISAimmunochromatographic test BACKGROUND Visceral Leishmaniasis (VL) is an infectious disease that is a significant cause of death among infants aged under 1 year and the elderly in Brazil. Serodiagnosis is a mainstay of VL elimination programs; however, it has significant limitations due to low accuracy. OBJECTIVE This study aimed to evaluate three recombinant Leishmania infantum proteins (rFc, rC9, and rA2) selected from previous proteomics and genomics analyses to develop enzyme-linked immunosorbent assay (ELISA) and immunochromatographic tests (ICT) for the serodiagnosis of human VL (HVL) and canine VL (CVL). METHODS A total of 186 human (70 L. infantum-infected symptomatic, 20 other disease-infected, and 96 healthy) and 185 canine (82 L. infantum-infected symptomatic, 27 L. infantum-infected asymptomatic, and 76 healthy) sera samples were used for antibody detection. FINDINGS Of the three proteins, rA2 (91.5% sensitivity and 87% specificity) and rC9 (95.7% sensitivity and 87.5% specificity) displayed the best performance in ELISA-HVL and ELISA-CVL, respectively. ICT-rA2 also displayed the best performance for HVL diagnosis (92.3% sensitivity and 88.0% specificity) and had high concordance with immunofluorescence antibody tests (IFAT), ELISA-rK39, IT-LEISH®, and ELISAEXT. ICT-rFc, ICT-rC9, and ICT-rA2 had sensitivities of 88.6%, 86.5%, and 87.0%, respectively, with specificity values of 84.0%, 92.0%, and 100%, respectively for CVL diagnosis. MAIN CONCLUSIONS The three antigens selected by us are promising candidates for VL diagnosis regardless of the test format, although the antigen combinations and test parameters may warrant further optimisation.Instituto Oswaldo Cruz, Ministério da Saúde2019-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100310Memórias do Instituto Oswaldo Cruz v.114 2019reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/0074-02760180405info:eu-repo/semantics/openAccessSantos,Anna Raquel Ribeiro dosSerufo,Ângela VieiraFigueiredo,Maria MartaGodoi,Lara CarvalhoVitório,Jéssica GardoneMarcelino,Andreza PainAvelar,Daniel Moreira deRodrigues,Fernandes Tenório GomesMachado-Coelho,George Luiz LinsMedeiros,Fernanda Alvarenga CardosoJerônimo,Selma Maria BezerraOliveira,Edward José deNascimento,Frederico CrepaldiTeixeira,Santuza Maria RibeiroGazzinelli,Ricardo TostesNagem,Ronaldo Alves PintoFernandes,Ana Paulaeng2020-04-25T17:52:57Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:22:30.818Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue
dc.title.none.fl_str_mv Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
title Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
spellingShingle Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
Santos,Anna Raquel Ribeiro dos
visceral leishmaniasis
recombinant proteins
diagnosis
ELISA
immunochromatographic test
title_short Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
title_full Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
title_fullStr Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
title_full_unstemmed Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
title_sort Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis
author Santos,Anna Raquel Ribeiro dos
author_facet Santos,Anna Raquel Ribeiro dos
Serufo,Ângela Vieira
Figueiredo,Maria Marta
Godoi,Lara Carvalho
Vitório,Jéssica Gardone
Marcelino,Andreza Pain
Avelar,Daniel Moreira de
Rodrigues,Fernandes Tenório Gomes
Machado-Coelho,George Luiz Lins
Medeiros,Fernanda Alvarenga Cardoso
Jerônimo,Selma Maria Bezerra
Oliveira,Edward José de
Nascimento,Frederico Crepaldi
Teixeira,Santuza Maria Ribeiro
Gazzinelli,Ricardo Tostes
Nagem,Ronaldo Alves Pinto
Fernandes,Ana Paula
author_role author
author2 Serufo,Ângela Vieira
Figueiredo,Maria Marta
Godoi,Lara Carvalho
Vitório,Jéssica Gardone
Marcelino,Andreza Pain
Avelar,Daniel Moreira de
Rodrigues,Fernandes Tenório Gomes
Machado-Coelho,George Luiz Lins
Medeiros,Fernanda Alvarenga Cardoso
Jerônimo,Selma Maria Bezerra
Oliveira,Edward José de
Nascimento,Frederico Crepaldi
Teixeira,Santuza Maria Ribeiro
Gazzinelli,Ricardo Tostes
Nagem,Ronaldo Alves Pinto
Fernandes,Ana Paula
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Santos,Anna Raquel Ribeiro dos
Serufo,Ângela Vieira
Figueiredo,Maria Marta
Godoi,Lara Carvalho
Vitório,Jéssica Gardone
Marcelino,Andreza Pain
Avelar,Daniel Moreira de
Rodrigues,Fernandes Tenório Gomes
Machado-Coelho,George Luiz Lins
Medeiros,Fernanda Alvarenga Cardoso
Jerônimo,Selma Maria Bezerra
Oliveira,Edward José de
Nascimento,Frederico Crepaldi
Teixeira,Santuza Maria Ribeiro
Gazzinelli,Ricardo Tostes
Nagem,Ronaldo Alves Pinto
Fernandes,Ana Paula
dc.subject.por.fl_str_mv visceral leishmaniasis
recombinant proteins
diagnosis
ELISA
immunochromatographic test
topic visceral leishmaniasis
recombinant proteins
diagnosis
ELISA
immunochromatographic test
dc.description.none.fl_txt_mv BACKGROUND Visceral Leishmaniasis (VL) is an infectious disease that is a significant cause of death among infants aged under 1 year and the elderly in Brazil. Serodiagnosis is a mainstay of VL elimination programs; however, it has significant limitations due to low accuracy. OBJECTIVE This study aimed to evaluate three recombinant Leishmania infantum proteins (rFc, rC9, and rA2) selected from previous proteomics and genomics analyses to develop enzyme-linked immunosorbent assay (ELISA) and immunochromatographic tests (ICT) for the serodiagnosis of human VL (HVL) and canine VL (CVL). METHODS A total of 186 human (70 L. infantum-infected symptomatic, 20 other disease-infected, and 96 healthy) and 185 canine (82 L. infantum-infected symptomatic, 27 L. infantum-infected asymptomatic, and 76 healthy) sera samples were used for antibody detection. FINDINGS Of the three proteins, rA2 (91.5% sensitivity and 87% specificity) and rC9 (95.7% sensitivity and 87.5% specificity) displayed the best performance in ELISA-HVL and ELISA-CVL, respectively. ICT-rA2 also displayed the best performance for HVL diagnosis (92.3% sensitivity and 88.0% specificity) and had high concordance with immunofluorescence antibody tests (IFAT), ELISA-rK39, IT-LEISH®, and ELISAEXT. ICT-rFc, ICT-rC9, and ICT-rA2 had sensitivities of 88.6%, 86.5%, and 87.0%, respectively, with specificity values of 84.0%, 92.0%, and 100%, respectively for CVL diagnosis. MAIN CONCLUSIONS The three antigens selected by us are promising candidates for VL diagnosis regardless of the test format, although the antigen combinations and test parameters may warrant further optimisation.
description BACKGROUND Visceral Leishmaniasis (VL) is an infectious disease that is a significant cause of death among infants aged under 1 year and the elderly in Brazil. Serodiagnosis is a mainstay of VL elimination programs; however, it has significant limitations due to low accuracy. OBJECTIVE This study aimed to evaluate three recombinant Leishmania infantum proteins (rFc, rC9, and rA2) selected from previous proteomics and genomics analyses to develop enzyme-linked immunosorbent assay (ELISA) and immunochromatographic tests (ICT) for the serodiagnosis of human VL (HVL) and canine VL (CVL). METHODS A total of 186 human (70 L. infantum-infected symptomatic, 20 other disease-infected, and 96 healthy) and 185 canine (82 L. infantum-infected symptomatic, 27 L. infantum-infected asymptomatic, and 76 healthy) sera samples were used for antibody detection. FINDINGS Of the three proteins, rA2 (91.5% sensitivity and 87% specificity) and rC9 (95.7% sensitivity and 87.5% specificity) displayed the best performance in ELISA-HVL and ELISA-CVL, respectively. ICT-rA2 also displayed the best performance for HVL diagnosis (92.3% sensitivity and 88.0% specificity) and had high concordance with immunofluorescence antibody tests (IFAT), ELISA-rK39, IT-LEISH®, and ELISAEXT. ICT-rFc, ICT-rC9, and ICT-rA2 had sensitivities of 88.6%, 86.5%, and 87.0%, respectively, with specificity values of 84.0%, 92.0%, and 100%, respectively for CVL diagnosis. MAIN CONCLUSIONS The three antigens selected by us are promising candidates for VL diagnosis regardless of the test format, although the antigen combinations and test parameters may warrant further optimisation.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100310
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100310
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0074-02760180405
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
dc.source.none.fl_str_mv Memórias do Instituto Oswaldo Cruz v.114 2019
reponame:Memórias do Instituto Oswaldo Cruz
instname:Fundação Oswaldo Cruz
instacron:FIOCRUZ
reponame_str Memórias do Instituto Oswaldo Cruz
collection Memórias do Instituto Oswaldo Cruz
instname_str Fundação Oswaldo Cruz
instacron_str FIOCRUZ
institution FIOCRUZ
repository.name.fl_str_mv Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz
repository.mail.fl_str_mv
_version_ 1669937727181684736